Endometrial Cancer
8 competing products in clinical development for Endometrial Cancer.
Pipeline by Phase
Phase 1/21
Phase 25
Phase 32
All Products (8)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Trastuzumab deruxtecan + Rilvegostomig + Pembrolizumab + Carboplatin + Paclitaxel + Docetaxel | Daiichi Sankyo | Phase 3 | Recruiting | 47 |
| Trastuzumab Deruxtecan + Chemotherapy | Daiichi Sankyo | Phase 3 | Recruiting | 47 |
| Datopotamab deruxtecan (Dato-DXd) + Capecitabine + 5-Fluorouracil + Volrustomig + Carboplatin + Bevacizumab + Rilvegostomig + Prednisone/ prednisolone + Cisplatin | Daiichi Sankyo | Phase 2 | Recruiting | 42 |
| Enfortumab Vedotin | Astellas Pharma | Phase 2 | Recruiting | 42 |
| Atezolizumab - 28 Day Cycle + Bevacizumab + Ipatasertib + Talazoparib + Trastuzumab emtansine + Tiragolumab + Atezolizumab - 21 Day Cycle + Inavolisib + Letrozole + Giredestrant + Abemaciclib | Eli Lilly | Phase 1/2 | Recruiting | 39 |
| Lenvatinib | Eisai | Phase 2 | Completed | 35 |
| Letrozole + Abemaciclib + LY3023414 + Metformin + Zotatifin + Gedatolisib | eFFECTOR Therapeutics | Phase 2 | Recruiting | 32 |
| Sodium Cridanimod + progestin therapy | Xenetic Biosciences | Phase 2 | Terminated | 17 |